Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker group BEFREE Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1-5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present. 30935383 2019
Entrez Id: 5324
Gene Symbol: PLAG1
PLAG1
0.100 Biomarker group BEFREE A significant (p ≤ 0.05) correlation between SUV<sub>max</sub> in PSMA-positive liver metastases and both size (ρ<sub>Spearman</sub> = 0.57) of metastases and PSA serum level (ρ<sub>Spearman</sub> = 0.60) was found. 31186052 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression group BEFREE Furthermore, immunostaining demonstrated that FLT3, LEPR, EGFR, and pSTAT3 were upregulated in metastases in HGSOC patients, with substantial patient-to-patient heterogeneity. 31129149 2019
Entrez Id: 2321
Gene Symbol: FLT1
FLT1
0.100 AlteredExpression group BEFREE Compared to primary high grade serous ovarian tumors, the related omental metastases showed higher expressions of VEGF-A (p = 0.022), VEGF-D (p = 0.010), and VEGFR1 (p = 0.046). 31200683 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE The study confirmed that patients with high PSA level and fast PSA increase are likely to be diagnosed with both, local relapse and metastases. 31568268 2019
Entrez Id: 1084
Gene Symbol: CEACAM3
CEACAM3
0.100 AlteredExpression group BEFREE A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992). 31542818 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker group BEFREE Using both GATA3 and SOX10 is recommended for confirming breast as the site of origin in metastases that lack estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, whereas the addition of AR is not helpful. 30468800 2019
Entrez Id: 10630
Gene Symbol: PDPN
PDPN
0.100 Biomarker group BEFREE With the discovery of molecules targeted at the lymphatic system such as lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and Podoplanin, many studies have been performed to determine the role of lymphatic endothelial cells (LECs) in tumor metastasis. 31289961 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation group BEFREE The mutant allele frequency of KRAS in metachronous metastases was higher in 6 cases (mean difference =% 25.5% (range, 9.5%-58.0%)) and lower in 3 cases (mean difference = 9.3% (range, 8.0-10.0%) compared with each of their primary tumors. 30888980 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.100 Biomarker group BEFREE Univariate logistic regression analysis showed that CEA (OR 1.056, 95% CI 1.007-1.107, p = 0.02) was the only preoperative predictor for occult metastases. 31186205 2019
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker group BEFREE Furthermore, elevated SUVmax, MTV, TLG, and choline peak levels, progesterone receptor (PR) negative finding, high Ki-67 expression, metastasis to an axillary lymph node, and advanced TNM staging were significantly associated with recurrence, and elevated SUVmax and TLG, PR-negative finding, and axillary node metastases were significantly associated with death. 30843007 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker group BEFREE A 72-year-old woman with estrogen receptor-negative human epidermal growth factor 2-positive breast cancer with distant metastases in the lung was admitted. 31842789 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.100 Biomarker group BEFREE Advanced age, marital status, right colon, poor differentiation, higher N stage, and bone metastasis were positively associated with all causes of early death, cancer-specific early death, and non-cancer early death, while higher T stage, positive carcinoembryonic antigen, and distant metastases (bone, lung, liver, and brain) were only positively associated with all causes of early death and cancer-specific early death. 31089875 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker group BEFREE Alternatively, fluorine-18 (<sup>18</sup>F)-labelled PSMA tracers are available, such as <sup>18</sup>F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. 31230088 2019
Entrez Id: 7431
Gene Symbol: VIM
VIM
0.100 AlteredExpression group BEFREE Decreased E-cadherin expression and increased Vimentin expression induced the EMT phenotype and promoted tumor metastasis. 31286874 2019
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 AlteredExpression group BEFREE The latter, an mRNA termed KRT20, has been shown to be over-expressed in metastases originating from colorectal cancer (CRC). 31121464 2019
Entrez Id: 960
Gene Symbol: CD44
CD44
0.100 Biomarker group BEFREE In 4T1-luc metastatic breast cancer model in mice, Sap-EGFR/CD44-NGs exhibited significant inhibition of tumor metastasis to lung at a small dose of 3.33 nmol Sap equiv./kg. 30699364 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker group BEFREE Relative to HR+/HER2- subtype, local recurrence was greater in HER2+ metastases (HR 3.20, 95% CI 1.78-5.75, p < 0.001), while patients with TNBC demonstrated higher rates of new brain metastases after initial treatment (HR 3.16, 95% CI 1.99-5.02, p < 0.001) and shorter time to salvage whole brain radiation (WBRT) (HR 3.79, 95% CI 1.36-10.56, p = 0.01) and salvage stereotactic radiation (HR 1.86, 95% CI 1.11-3.10, p = 0.02). 30982195 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker group BEFREE At multivariate analysis, age, sex, histotype, vascular invasion, T and N parameters, and PSMA positivity were significant predictors of distant metastases.The AUC was 0.92. 31617002 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation group BEFREE Multivariate analysis showed that extra metastases (HR = 2.240, P = 0.001) and smoking history (HR = 2.048, P = 0.013) were independent prognostic factors for OS in lung adenocarcinoma patients with EGFR uncommon mutations. 30885350 2019
Entrez Id: 7431
Gene Symbol: VIM
VIM
0.100 Biomarker group BEFREE The present work examines whether these actions are associated with changes in the expression of cadherins, β-catenin and vimentin, established markers of the Epithelial-Mesenchymal Transition (EMT) which has been linked with cell migration and tumour metastasis. 30403907 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression group BEFREE PD-1 and PD-L1 expression was present in biopsy samples (47% and 53%, respectively), absent in resections, and present in metastases (40% and 47%). 31842180 2019
Entrez Id: 3732
Gene Symbol: CD82
CD82
0.100 Biomarker group BEFREE Kangai 1 (KAI1) is considered as a suppressor gene of tumor metastasis. 31725636 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker group BEFREE 68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level. 30540597 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 AlteredExpression group BEFREE We found that four E3 ubiquitin ligases (UHRF1, BRCA1, TRAIP and HLTF) and one regulator of ubiquitin E3 activity DCUN1D1 that were dramatically up-regulated in cancer were significantly associated with tumor metastasis and patient's poor prognosis both in two transcriptome data sets. 30528265 2019